The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer

BACKGROUND: In the phase III RECOURSE trial, trifluridine/tipiracil (TAS-102) extended overall survival (OS) and progression-free survival (PFS) with an acceptable toxicity profile in patients with metastatic colorectal cancer refractory or intolerant to standard therapies. The present analysis inve...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Cutsem, Eric, Mayer, Robert J., Laurent, Stéphanie, Winkler, Robert, Grávalos, Cristina, Benavides, Manuel, Longo-Munoz, Federico, Portales, Fabienne, Ciardiello, Fortunato, Siena, Salvatore, Yamaguchi, Kensei, Muro, Kei, Denda, Tadamichi, Tsuji, Yasushi, Makris, Lukas, Loehrer, Patrick, Lenz, Heinz-Josef, Ohtsu, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493695/
https://www.ncbi.nlm.nih.gov/pubmed/29274618
http://dx.doi.org/10.1016/j.ejca.2017.10.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493695/
https://www.ncbi.nlm.nih.gov/pubmed/29274618
http://dx.doi.org/10.1016/j.ejca.2017.10.009

Ejemplares similares